脉金生物医药科技（上海）有限公司 Wangjin Biomedical Technology (Shanghai) Co. LTD Mediaroom

Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED

* Inmagene exercised its option under the previously announced collaboration agreement to obtain ...

2024-02-02 22:00 1490

Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata

* IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12...

2023-10-13 20:00 1342

Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function

SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage ...

2023-09-21 21:00 3576

David Topper Joined Inmagene as CFO

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stag...

2023-09-05 20:00 1331

Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study

* IMG-007 has the potential to provide Q12W or less frequent dosing based on an extended half-lif...

2023-08-18 19:00 4491

Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis

SAN DIEGO, SHANGHAI and SYDNEY, Aug. 15, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagen...

2023-08-15 22:50 1827

Inmagene to Participate in the Jefferies Healthcare Conference on June 8

SAN DIEGO, SHANGHAI and SYDNEY, May 30, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagen...

2023-05-30 20:00 2030

IMG-004 demonstrated extended half-life and durable pharmacodynamic characteristics in a Phase 1 study

SAN DIEGO, SHANGHAI and SYDNEY, April 28, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmage...

2023-04-28 17:00 1693

Izokibep Phase 2b/3 Hidradenitis Suppurative Data Presented at the 2023 American Academy of Dermatology Annual Meeting

* At 12 weeks, participants achieved high orders of HiSCR responses (HiSCR75 and above), includin...

2023-03-20 08:41 2171

Inmagene receives IND clearance for IMG-008, a long-acting IL-36R mAb

SAN DIEGO, SHANGHAI and SYDNEY, Feb. 6, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene...

2023-02-06 18:00 1841

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-004

SAN DIEGO, SHANGHAI and HONG KONG, Aug. 9, 2022 /PRNewswire/ -- Inmagene Biopharmaceutical ("Inmage...

2022-08-09 12:00 1540

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inma...

2022-07-06 12:00 1541

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

SAN DIEGO and SHANGHAI and SYDNEY, April 30, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inm...

2022-05-01 06:00 3572

Inmagene files two international patent applications

SHANGHAI and SAN DIEGO and HANGZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Inmagene Biopharmaceutica...

2021-11-17 18:30 1197

Inmagene and Kissei Enter into an Exclusive License Agreement for Fostamatinib in China

SHANGHAI and SAN DIEGO and NAGANO, Japan, Aug. 5, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ...

2021-08-05 14:00 1928

Inmagene R&D Team expands with two new senior members joining the Company

SAN DIEGO and SHANGHAI and HANGZHOU, China, April 7, 2021 /PRNewswire/ -- Inmagene Biopharmaceutica...

2021-04-07 09:00 16923

Inmagene launched U.S. subsidiary; Dr. Jean-Louis Saillot joined the company.

SAN DIEGO, Calif. and SHANGHAI, Feb. 2, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene...

2021-02-02 14:48 2086

Inmagene Biopharmaceuticals closed $21 million Series B financing, making the total raised to date over $40 million

SHANGHAI, Nov. 8, 2020 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), announced today ...

2020-11-09 08:00 1986

Latest News